Hepatocyte growth factor (HGF) was reported to be effective in preventing acute graft-versus-host disease (GVHD) in a murine model. We examined serum HGF concentrations in 38 patients receiving allogeneic bone marrow transplants, and investigated the relationship of serum HGF concentrations to severity of acute GVHD. More HGF was present in sera from patients with than without acute GVHD. Serum HGF correlated significantly with grade of acute GVHD. Furthermore, serum HGF correlated with serum concentrations of Creactive protein, ␥-glutamyltranspeptidase (GTP), and aspartate aminotransferase (AST). Serum concentrations of HGF in transplanted patients without GVHD were consistently low, while those in patients with acute GVHD increased with exacerbation. We conclude that HGF was produced during induction of the GVH reaction, and probably increased as a physiological response. Bone Marrow Transplantation (2001) 28, 197-200. 
Hepatocyte growth factor (HGF) was originally identified and cloned as a potent mitogen for hepatocytes.
1,2 HGF has mitogenic, motogenic and morphogenic effects on various epithelial and endothelial cells, [3] [4] [5] through the activation of c-met proto-oncogene receptors. 6 HGF also has anti-apoptotic activity, 7, 8 and promotes hematopoiesis by acting synergistically with hematopoietic cytokines. 9, 10 In preclinical studies, HGF enhanced liver and kidney regeneration, as well as preventing acute renal failure. 3 HGF also suppressed induction of hepatic cirrhosis by dimethylnitrosamine, 11, 12 suggesting that HGF has considerable potential for facilitating repair of tissue-damage. Recently, we reported that gene therapy to produce HGF overexpression was effective in preventing acute graft-versus-host disease (GVHD) in a murine model. 13, 14 We there- fore examined serum HGF concentrations in 38 patients undergoing allogeneic bone marrow transplantation (BMT) with respect to the relationship between serum HGF and acute GVHD.
Materials and methods

Patients
Thirty-eight patients receiving allogeneic BMT were studied after giving informed consent. The patients were hospitalized at Hyogo College of Medicine during the period from 1996 to 2000. Acute GVHD was graded as 0, I, II, III, or IV according to Glucksberg et al. 15 The 38 patients were divided into three groups: 20 with acute GVHD of grade 0; six with grade I and 12 with grades II to IV. As shown in Table 1 , age ranges of patients with acute GVHD of grade 0, I, and II to IV were 19 to 50 years, 19 to 44 years, and 16 to 41 years (medians 33 years, 35 years, and 25 years), respectively, representing no difference in age distribution. No difference in gender distribution was noted between these GVHD-defined groups. Among the 20 patients with grade 0 acute GVHD, five patients had acute lymphoblastic leukemia (ALL); three, acute myelogenous leukemia (AML); five, chronic myelogenous leukemia (CML); two, myelodysplastic syndromes (MDS); two, nonHodgkin lymphoma (NHL); and three, severe aplastic anemia (SAA). The six patients with grade I included two with ALL, two with CML, one with MDS, and one with SAA; the 12 patients with grades II to IV included six with ALL, four with AML, and two with CML. All 38 patients received bone marrow transplants from HLA-identical donors. The distribution of related vs unrelated donors in acute GVHD of grades 0, I, and II to IV were 12/8, 1/5 and 2/10, respectively (Table 1) . Related-donor grafts were more numerous among patients with grade 0 than unrelated-donor grafts, while unrelated-donor grafts were more numerous among patients with grades I or II to IV than related-donor grafts.
Blood samples
Blood samples were drawn from 38 patients and 112 samples were analyzed. In patients with multiple blood samples, the highest level of HGF was used for statistical analysis with respect to grade of GVHD. In patients without GVHD, blood samples were collected 30 to 60 days after BMT. In several patients, blood samples were collected serially from 0 to 120 days after BMT. Blood samples were allowed to coagulate for 30 to 60 min and then centrifuged at 3000 r.p.m. for 10 min. Serum was separated and stored at Ϫ70°C. Control blood samples were obtained from 18 healthy individuals.
HGF assay
Concentrations of HGF in sera were determined with an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA), involving a specific sandwich method with a mouse monoclonal antibody against recombinant HGF, as well as mouse monoclonal antibody labeled with peroxidase. If the concentration of HGF exceeded the assay range, serum was diluted for assay. The standard curve for HGF showed linearity from 78 to 5000 pg/ml. Each serum sample was analyzed in duplicate.
Clinical laboratory variables
Routine laboratory data including serum concentrations of C-reactive protein (CRP), ␥-glutamyltranspeptidase (␥-GPT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total bilirubin, creatinine, blood urea nitrogen (BUN), total protein, and albumin were obtained from medical records.
Statistical analysis
The Student's t test was used for analysis of unpaired samples. Relationships between serum HGF and clinical variables were examined using Spearman's correlation coefficient. Serum HGF concentrations in groups representing acute GVHD of grades 0, I, and II to IV are presented as the mean Ϯ standard error (s.e.). Analyses were performed using a statistical software package (StatView; SAS Institute, Cary, NC, 1998).
Results
Serum HGF in patients with or without acute GVHD
Serum HGF concentrations in patients with no acute GVHD (grade 0) ranged from 223 to 934 pg/ml (mean Ϯ s.e., 555 Ϯ 42). Serum HGF in grade I ranged from 759 to 7762 pg/ml, (mean, 2293 Ϯ 1100), and those in grades II to IV ranged from 706 to 11676 pg/ml, (mean, 3098 Ϯ 967). As shown in Figure 1 , the serum HGF concentration for grade I and grades II to IV was significantly higher than for grade 0 (P = 0.0061 and 0.0018, respectively). However, no significant difference was found between serum HGF for grade I and that for grades II to IV. The serum concentration of HGF in 18 normal individuals ranged from 202 to 634 pg/ml (mean, 397 Ϯ 28), and was significantly lower than for grade 0 (P = 0.004). There was no correlation between the serum HGF concentrations and other parameters of BMT, that is disease, patients' status, previous treatment or pre-conditioning regimen (data not shown). Table 2 shows the relationship of clinical laboratory data to serum HGF. Serum HGF concentrations exhibited a positive correlation with CRP (P = 0.0056), ␥-GPT (P = 0.0088), and AST (P = 0.0057). HGF did not show a correlation with ALT, total bilirubin, ALP, LDH, creatinine, BUN, total protein, or albumin.
Relationship between serum HGF and clinical laboratory variables
Changes in serum HGF concentration in patients with or without acute GVHD
We serially measured serum HGF concentrations in several patients after BMT. Four examples of changes in serum HGF after BMT are shown in Figure 2 . Serum concentration of HGF increased with exacerbation of GVHD in patients with grade II-IV GVHD (cases 1 and 2), while those in patients with grade I or without GVHD were consistently low (cases 3 and 4). Serum concentration of CRP did not correlate with serum HGF in those cases. 
Discussion
HGF, a ligand for the c-met proto-oncogene product of receptor tyrosine kinase, is a well-characterized multifuncBone Marrow Transplantation tional growth factor that affects a wide variety of cells. 16 Recently, we reported that treatment with HGF is effective for preventing acute GVHD in a murine model. 13, 14 We also examined serum HGF concentrations in 38 patients receiving allogeneic BMT, and found that HGF clearly correlated with severity of acute GVHD. To our knowledge, this is the first report indicating that HGF is produced in response to GVHD.
Serum HGF concentrations have been reported to be elevated in liver disease, chronic renal failure, systemic inflammatory response syndrome (SIRS), and malignant diseases such as leukemia, breast cancer, and gastric cancer. [17] [18] [19] [20] Circulating HGF is increased in the presence of septic complications. Sakon et al 21 reported that HGF in serum was elevated in patients with sepsis, and also correlated with CRP in patients with nonseptic SIRS. In our study, serum CRP concentrations correlated significantly with HGF in serum. Elevation of CRP presumably was induced by inflammatory cytokines. As shown in Figure 2 , cases 1 and 3 representing mild or moderate acute GVHD showed no elevation of CRP, but their HGF concentrations increased in parallel with signs of GVHD. HGF production was thought to be induced by the GVH reaction. However, as acute GVHD tended to be complicated by bacterial and viral infections, clear discrimination of cytokine production in the immunological GVH reaction from that occurring in infections was difficult. Based on the murine experiment, 13, 14 the serum HGF concentration of 2000 pg/ml was effective for preventing GVHD. In our study, the serum HGF concentration in patients with acute GVHD was the same or higher than serum HGF of 2000 pg/ml (Figure 1) . Thus, the serum concentration of HGF in patients with acute GVHD was elevated to a high enough level of HGF to prevent GVHD in a murine model.
Our results showed that serum AST and ␥-GPT correlated significantly with HGF. Shiota et al 17 reported that serum HGF was increased in patients with acute or chronic hepatitis, and exhibited a positive correlation with total bilirubin, indocyanine green retention, and AST. An increase in AST was found to be a common factor correlating with HGF in acute GVHD, as well as hepatic diseases. In our BMT patients, none had severe hepatic GVHD with a rise in total bilirubin. However, patients with acute GVHD show an elevation of ␥-GPT, probably reflecting subclinical hepatic GVHD. The significant correlation between HGF and ␥-GTP probably can be attributed to liver damage from GVHD.
In conclusion, HGF production increased in acute GVHD and correlated with severity of GVHD in patients with allogeneic BMT. HGF is probably produced by a physiological response, and might ameliorate tissue damage from acute GVHD. 
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